Arena Pharma (ARNA) Tops Q3 EPS by 4c

Arena Pharma (NASDAQ: ARNA) reported Q3 EPS of ($0.70), $0.04 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $2.32 million.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation